Hsi-Tien Wu

Dr. Hsi-Tien Wu

National Chiayi University
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
WHWen-Yeh Hsieh
Wen-Yeh Hsieh
CLCheng-Han Lin
Cheng-Han Lin
TLTzu-Ching Lin
Tzu-Ching Lin
CLChao-Hsu Lin
Chao-Hsu Lin
HCHui-Fang Chang
Hui-Fang Chang
CLChih-Sheng Lin
Chih-Sheng Lin
The COVID-19 pandemic is an ongoing global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2020–2021. COVID-19 is becoming one of the most fatal pandemics in history and brings a huge challenge to the global healthcare system. Opportune detection, confinement, and early treatment of infected cases present the first step in combating COVID-19. Diagnosis via viral nucleic acid amplification tests (NAATs) is frequently employed and considered the standard procedure. However, with an increasing urge for point-of-care tests, rapid and cheaper immunoassays are widely utilized, such as lateral flow immunoassay (LFIA), which can be used for rapid, early, and large-scale detection of SARS-CoV-2 infection. In this narrative review, the principle and technique of LFIA applied in COVID-19 antigen and antibody detection are introduced. The diagnostic sensitivity and specificity of the commercial LFIA tests are outlined and compared. Generally, LFIA antigen tests for SARS-CoV-2 are less sensitive than viral NAATs, the “gold standard” for clinical COVID-19 diagnosis. However, antigen tests can be used for rapid and mass testing in high-risk congregate housing to quickly identify people with COVID-19, implementing infection prevention and control measures, thus preventing transmission. LFIA anti-SARS-CoV-2 antibody tests, IgM and/or IgG, known as serology tests, are used for identification if a person has previously been exposed to the virus or vaccine immunization. Notably, advanced techniques, such as LFT-based CRISPR-Cas9 and surface-enhanced Raman spectroscopy (SERS), have added new dimensions to the COVID-19 diagnosis and are also discussed in this review.

6 December 2021 in Sustainability
Verified
Journal Article
Open access
PDF file
CKChiu-Mei Kuo
Chiu-Mei Kuo
YSYu-Ling Sun
Yu-Ling Sun
CLCheng-Han Lin
Cheng-Han Lin
CLChao-Hsu Lin
Chao-Hsu Lin
HWHsi-Tien Wu
Hsi-Tien Wu
CLChih-Sheng Lin
Chih-Sheng Lin
Microalgae-based carbon dioxide (CO2) biofixation and biorefinery are the most efficient methods of biological CO2 reduction and reutilization. The diversification and high-value byproducts of microalgal biomass, known as microalgae-based biorefinery, are considered the most promising platforms for the sustainable development of energy and the environment, in addition to the improvement and integration of microalgal cultivation, scale-up, harvest, and extraction technologies. In this review, the factors influencing CO2 biofixation by microalgae, including microalgal strains, flue gas, wastewater, light, pH, temperature, and microalgae cultivation systems are summarized. Moreover, the biorefinery of Chlorella biomass for producing biofuels and its byproducts, such as fine chemicals, feed additives, and high-value products, are also discussed. The technical and economic assessments (TEAs) and life cycle assessments (LCAs) are introduced to evaluate the sustainability of microalgae CO2 fixation technology. This review provides detailed insights on the adjusted factors of microalgal cultivation to establish sustainable biological CO2 fixation technology, and the diversified applications of microalgal biomass in biorefinery. The economic and environmental sustainability, and the limitations and needs of microalgal CO2 fixation, are discussed. Finally, future research directions are provided for CO2 reduction by microalgae.

6 December 2012 in Applied Biochemistry and Biotechnology
Verified
Journal Article
Closed access
PDF file
HWHsi-Tien Wu
Hsi-Tien Wu
SSSyu Sheng Sie
Syu Sheng Sie
TKTang Ching Kuan
Tang Ching Kuan
CLChih Sheng Lin
Chih Sheng Lin

1 January 2018 in Experimental Animals
Verified
Journal Article
Open access
PDF file
HWHsi-Tien Wu
Hsi-Tien Wu
YCYa-Wen Chuang
Ya-Wen Chuang
CHCheng-Pu Huang
Cheng-Pu Huang
MCMingHuang Chang
MingHuang Chang
Angiotensin converting enzyme II (ACE2), an angiotensin converting enzyme (ACE) homologue that displays antagonist effects on ACE/angiotensin II (Ang II) axis in renin-angiotensin system (RAS), could play a protective role against liver damages. The purpose of this study is to investigate whether inflammation-mediated liver injury could be affected by ACE2 derived pathways in the RAS. Eight-weeks-old wild-type (WT; C57BL/6) and Ace2 KO (hemizygous Ace2-/y) male mice were used to induce liver fibrosis by thioacetamide (TAA) administration (0, 100, and 200 mg/kg BW). The mice administrated with TAA could be successfully induced liver fibrosis in a TAA-dose dependent manner. Compared to WT mice, the results show that Ace2 KO mice have high sensitive, and developed more serious reaction of hepatic inflammation and fibrosis by TAA administration. The physiological and pathological examinations demonstrated higher serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) levels, infiltration of white blood cells and fibrotic lesions within liver in the Ace2 KO mice. The severe liver damage of Ace2 KO mice were also confirmed by the evidence of higher expression of hepatic inflammation-related genes (IL-6 and Tnf) and fibrosis-related genes (Col1a1, Timp1 and Mmp9). Ace2 gene deficiency could lead to a severe inflammation and collagen remodeling in the liver administrated by TAA, and the responses lead the pathogenesis of liver fibrosis. Our studies provided the main messages and favorable study directions of relationship of Ace2 and liver disease.

22 August 2020 in Cell Biology International
Verified
Journal Article
Closed access
PDF file
HCHung‐Chiuan Chen
Hung‐Chiuan Chen
Suresh AwaleSuresh Awale
Suresh Awale
CWChean‐Ping Wu
Chean‐Ping Wu
HLHu‐Hui Lee
Hu‐Hui Lee
HWHsi-Tien Wu
Hsi-Tien Wu

1 March 2011 in Applied Biochemistry and Biotechnology
Verified
Journal Article
Closed access
PDF file
YLYu Chia Liu
Yu Chia Liu
WLWin Yu Lin
Win Yu Lin
YJYa Ru Jhang
Ya Ru Jhang
SHSing Hui Huang
Sing Hui Huang
CWChean Ping Wu
Chean Ping Wu
HWHsi-Tien Wu
Hsi-Tien Wu